바다이야기 고래 출현 18.rak136.top 바로가기 릴온라인
바다이야기 고래 출현 62.rak136.top 릴온라인
바다이야기 고래 출현 35.rak136.top 릴온라인
바다이야기 고래 출현 51.rak136.top 릴온라인
바다이야기 고래 출현 91.rak136.top 릴온라인
바다이야기 고래 출현 11.rak136.top 릴온라인
바다이야기 고래 출현 95.rak136.top 릴온라인
바다이야기 고래 출현 2.rak136.top 릴온라인
바다이야기 고래 출현 82.rak136.top 릴온라인
바다이야기 고래 출현 0.rak136.top 릴온라인
바다이야기 고래 출현 92.rak136.top 릴온라인
백경예시 우주전함야마토2199 알라딘릴게임오락실 온라인게임 바다이야기부활 릴게임 공략법 오션파라다이스사이트 파칭코 어플 릴게임 온라인 씨엔조이 일본경륜 오션파라다이스 예시 신바다이야기 오징어 릴게임 종합릴게임 배터리게임 황금성 슬롯머신 무료 오리지널야마토 오션파라다이스다운 중고게임기 매매 신오션파라다이스 신천지 게임 모바일 바다 이야기 다운 손오공 바다이야기부활 신규슬롯사이트 알라딘게임예시 pc 바다 이야기 다운 이벤트릴게임 백경다운로드 슬롯머신 777 야마토2게임동영상 해적게임 파칭코 바다이야기 예시 알라딘게임예시 잘터지는 슬롯 무료충전바다이야기 모바일파칭코 바다이야기 공략법 파친코 중고게임기 매매 백경 오션파라 다이스다운 릴게임5만릴게임사이다 릴게임 먹튀보증 야마토다운 사설경정 슬롯 확률 릴게임 먹튀보증 릴게임안전사이트 카지노 슬롯 게임 추천 황금성3하는곳 릴게임먹튀검증 카카오야마토먹튀 백경온라인 야마토2 pc버전 황금성하는곳 손오공게임하기 오션파라 다이스하는방법 바다이야기 2화 파라 다이스 오션 슬롯 게임사 추천 바다신2게임 체리마스터 pc용 바다이야기 모바일게임 블랙잭하는법 체리게임주소 오션파라다이스게임사이트 안전 슬롯사이트 메가슬롯 온라인신천지 카카오야마토 최신게임 매장판 슬롯무료게임 바다이야기 무료게임 종합 릴게임 야마토게임장주소 체리마스터 공략 신천지게임사이트 최신 인터넷게임 모바일야마토5게임 오션파라다이스 먹튀 프라그마틱환수율 오션파라 다이스다운 릴게임연타 슬롯머신 무료게임 강원랜드 슬롯 잘 터지는 기계 황금성배당 강원랜드게임종류 야마토5다운로드게임사이트 다빈치무료릴게임 무료야마토릴게임 온라인 릴게임 사이트 다빈치 릴게임 먹튀 바다이야기노무현 온라인 슬롯 머신 게임 슬롯 게시판 바다이야기 황금고래 인터넷야마토릴게임 인터넷손오공게임 알라딘게임 바다이야기게임방법 프라그마틱 슬롯 추천 릴게임신천지사이트 황금성게임후기 소액 슬롯 추천 바다이야기 넥슨 바다이야기 상어 모바일 야마토 체리마스터게임 블랙잭하는법 메이저 슬롯사이트 모바일릴게임 종류 인터넷바다이야기게임 뽀빠이릴게임 매장판황금성 바다시즌7 릴게임가입머니 무료슬롯게임 바다이야기동영상 다빈치릴게임먹튀 바다이야기2화 뉴야마토 This article was released as Pharm Edaily Premium Content on September 24, 2025, at 7:16 AM.
[Shin-Min Joon, Edaily Reporter] On September 23 in the South Korean pharmaceutical and biotechnology stock market, remarkable stock surges were seen in Celltrion, Protina, and Viol. Celltrion’s share price rose on expectations that tariff risk would be alleviated by acquir하나그린스팩 주식
ing a US biologics manufacturing facility from global pharma company Eli Lilly.
Protina’s stock jumped sharply after securing a clinical specimen analysis service contract with a multinatio모바일 바다이야기
nal company. Viol which is facing delisting procedures on KOSDAQ hit the daily upper price limit for three consecutive days driven by a dominance of buying amid decreased trading volume.
가치주펀드
◇Celltrion Acquires Eli Lilly’s Biologics Facility for 460 Billion Won
According to KG Zeroin’s MP Doctor (formerly MarketPoint), Celltr바다이야기 모바일게임
ion’s stock closed at won 184,200 up 8.93% from the previous trading day. After falling the day before the share price rebounded buoyed by the announcement of a won 460 billion acquisition of Eli Lill1%만 알고있는 증권정보
y’s biologics manufacturing plant in Branchburg New Jersey, U.S. The transaction lifted investor expectations of reduced tariff risk.
The facility is a large scale campus on 45,000 pyung (149,000 m²), comprising four buildings: a production facility, a logistics warehouse, a technical support wing, and an operations building. Because Celltrion owns unused land of about 11,000 pyung (36,400 m²) on the site, it has room for expansion, which could allow the company to respond preemptively to rising market demand.
Though the headline purchase price is 460 billion won total investment including initial operating expenses and facility expansion is expected to reach won 1.4 trillion over the long term. Celltrion plans to finance it via borrowing and inject the capital into its U.S. subsidiary Celltrion USA, through a paid in capital increase.
In an online press briefing Celltrion Group Chairman Seo Jung jin said “If the U.S. demands tariffs, investing in the U.S. is the answer.”
He added “To deal with tariff issues, we’ve maintained inventory for two years.” He also said that before its domestic production facility is ready Celltrion will sell products made in the USA under contract manufacturing (CMO) agreements. Negotiations to acquire the New Jersey facility from Eli Lilly began about six months ago.
Though other companies vied for it Celltrion was designated as preferred bidder. The formal contract was finalized on September 20. Half of the production lines in the purchased facility will continue manufacturing Eli Lilly products under contract while the other half will be used for Celltrion’s own products. Full scale production including transfer of operations from Lilly validating Celltrion’s own products, and obtaining necessary re approvals is expected in the second half of next year.
The biotech industry views this move as resolving tariff related uncertainties for Celltrion. In addition to mitigating tariff risk industry observers anticipate that Celltrion’s earnings will improve thanks to expansion of its contract manufacturing business. New revenue from CMO contracts with Eli Lilly is expected. The company plans to increase capacity, targeting a facility size about 1.5 times larger than its Incheon Songdo Plant 2. Accordingly its operating margin is expected to gradually rise.
Chairman Seo also noted “The facility isn’t just manufacturing staff it includes R&D personnel and production technology teams making it a natural opportunity to relocate or integrate U.S. based laboratories.” This he said would strengthen a bilateral research system anchored in Songdo, Korea and New Jersey U.S.
◇Protina Secures Global Contract for Clinical Specimen Analysis Services
Protina’s stock closed at won 43,400 up 29.94% compared to the previous day hitting its daily upper bound. The surge followed the company’s securing of a contract worth about 1.2 billion won to supply clinical specimen analysis services to a multinational U.S. pharmaceutical firm. Established in 2015 as a KAIST faculty startup Protina is a big data protein company whose core competency is analyzing protein protein interactions (PPI).
Protina operates a single molecule protein interaction (SPID) platform called PPI Landscape used to quantify interactions among proteins across various sample types feeding into drug discovery.
By rapidly acquiring large datasets of antigen antibody interaction data the platform helps in developing biobetters or discovering new drug candidates. Understanding the composition of protein complexes and interaction networks more precisely boosts success probabilities in identifying disease targets, developing biomarkers and designing modulators.
Notably Protina has drawn attention through an investment by global investment bank JPMorgan. As of July 10 the Asia Pacific branch of JPMorgan Asset Management held a 2.89% stake. Protina has said that JPMorgan’s favorable evaluation of the business potential of its PPI Landscape platform, even before the stock listing, was a key reason for the investment.
A company official commented “The contract shows that our unique technology has been validated which seems to have positively influenced the stock price.”
◇Viol Approaches KOSDAQ Delisting, Stock Hits Three Day Upper Limit
Viol’s share price rose 29.90% from the previous day to won?27,150, marking its third consecutive day at the daily upper price limit. The surge is attributed to a diminished trading volume creating a situation where buying pressure dominates. Indeed, the trading volume dropped from 882,874 shares on September 21 to just 260,321 shares on this day.
Recently, Viol’s majority shareholder changed. In May VIG Partners acquired 56.9% of Viol’s management rights from DMS for 367.9 billion won. Through a tender offer from June 18 to July 7, VIG Partners increased its shareholding to around 85%, then continued purchasing remaining shares on the open market. To prepare for delisting, VIG Partners formed a special purpose company called Vienna Investment Vehicle in June. On July 9 it disclosed the possibility of a cash?settled comprehensive share exchange. This procedure would force purchase of minority shareholders’ shares in order to delist. Once shareholding exceeds 95%, Viol may directly apply for delisting with the Korea Exchange.
If the share purchase agreement between DMS and VIG Partners concludes successfully on September 29 VIG Partners’ ownership will rise to 96.57%. Delisting generally proceeds via board resolution followed by convening a shareholders’ meeting. If approved via a special resolution, the company applies for delisting with the Korea Exchange. After passing the exchange’s review a period of organized trading for remaining shares is set before final delisting occurs.
Viol a medical device company specializing in cosmetic skin beauty equipment, has consistently posted record revenues and operating profits. Last year it recorded sales of 58.2 billion won and operating profit of 36.1 billion won.
Its operating margin of 62% was among the highest in the industry. The company was first to develop a high frequency cosmetic device using microneedles as small as 300 micrometers (μm).
An official at Viol said “There is no particular new development the reduced trading volume has made the buying side more noticeable.”
신민준 (adonis@edaily.co.kr)
조회 : 32
